D M Moreira1, D M de O Freitas2,3, J C Nickel4, G L Andriole5, R Castro-Santamaria6, S J Freedland7. 1. Department of Urology, University of Illinois at Chicago, Chicago, IL, USA. 2. University of Southern California, Los Angeles, CA, USA. 3. Nossa Senhora da Conceição Hospital, Porto Alegre, Brazil. 4. Department of Urology, Queen's University, Kingston, ON, Canada. 5. Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA. 6. GlaxoSmithKline, Global R&D, King of Prussia, Pennsylvania, PA, USA. 7. Division of Urology, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Abstract
BACKGROUND: To evaluate whether the presence of both prostate atrophy (PA) and chronic prostate inflammation (CPI) in the same biopsy and in the same biopsy core are associated with prostate cancer (PCa) risk and grade in repeat biopsies. METHODS: Retrospective analyses of 6132 men who were 50-75 years old undergoing 2-year repeat prostate biopsy after a negative baseline biopsy for PCa in the REduction by DUtasteride of prostate Cancer Events (REDUCE) study. PA, CPI and PCa were determined by central pathology. The association of baseline PA and CPI with 2-year repeat biopsy cancer status and grade was evaluated with χ2 test and logistic regression controlling clinicopathological features. RESULTS: PA, CPI and both were detected in 583 (9.5%), 1063 (17.4%) and 3675 (59.9%) baseline biopsies, respectively. Compared with biopsies with neither PA nor CPI, the presence of PA (odds ratio (OR)=0.73, 95% confidence interval (CI)=0.57-0.93), CPI (OR=0.72, 95% CI=0.58-0.88) and both (OR=0.54, 95% CI=0.45-0.64) were associated with lower PCa risk in the 2-year repeat prostate biopsy. Results were similar in multivariable analysis. Among subjects with both PA and CPI, those with both findings in the same core had even lower PCa risk compared with PA and CPI in different cores (univariable OR=0.68, 95% CI=0.51-0.91; multivariable OR=0.73, 95% CI=0.54-0.99). Combination of PA and CPI was associated with lower risk of high-grade PCa. CONCLUSIONS: The presence of both PA and CPI in baseline biopsies, especially in the same core, was associated with lower PCa risk and grade. The presence and topographical distribution of PA and CPI may be used in PCa risk stratification.
BACKGROUND: To evaluate whether the presence of both prostate atrophy (PA) and chronic prostate inflammation (CPI) in the same biopsy and in the same biopsy core are associated with prostate cancer (PCa) risk and grade in repeat biopsies. METHODS: Retrospective analyses of 6132 men who were 50-75 years old undergoing 2-year repeat prostate biopsy after a negative baseline biopsy for PCa in the REduction by DUtasteride of prostate Cancer Events (REDUCE) study. PA, CPI and PCa were determined by central pathology. The association of baseline PA and CPI with 2-year repeat biopsy cancer status and grade was evaluated with χ2 test and logistic regression controlling clinicopathological features. RESULTS:PA, CPI and both were detected in 583 (9.5%), 1063 (17.4%) and 3675 (59.9%) baseline biopsies, respectively. Compared with biopsies with neither PA nor CPI, the presence of PA (odds ratio (OR)=0.73, 95% confidence interval (CI)=0.57-0.93), CPI (OR=0.72, 95% CI=0.58-0.88) and both (OR=0.54, 95% CI=0.45-0.64) were associated with lower PCa risk in the 2-year repeat prostate biopsy. Results were similar in multivariable analysis. Among subjects with both PA and CPI, those with both findings in the same core had even lower PCa risk compared with PA and CPI in different cores (univariable OR=0.68, 95% CI=0.51-0.91; multivariable OR=0.73, 95% CI=0.54-0.99). Combination of PA and CPI was associated with lower risk of high-grade PCa. CONCLUSIONS: The presence of both PA and CPI in baseline biopsies, especially in the same core, was associated with lower PCa risk and grade. The presence and topographical distribution of PA and CPI may be used in PCa risk stratification.
Authors: Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster Journal: N Engl J Med Date: 2010-04-01 Impact factor: 91.245
Authors: C Wu; D M Moreira; L Gerber; R S Rittmaster; G L Andriole; S J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2011-06-28 Impact factor: 5.554
Authors: Pol Servian; Ana Celma; Jacques Planas; Jose Placer; Inés M de Torres; Mireia Olivan; Juan Morote Journal: Prostate Date: 2015-07-17 Impact factor: 4.104
Authors: Daniel M Freitas; Gerald L Andriole; Ramiro Castro-Santamaria; Stephen J Freedland; Daniel M Moreira Journal: Urology Date: 2016-12-23 Impact factor: 2.649
Authors: Nicolas B Delongchamps; Gustavo de la Roza; Vishal Chandan; Richard Jones; Robert Sunheimer; Gregory Threatte; Mary Jumbelic; Gabriel P Haas Journal: J Urol Date: 2008-03-17 Impact factor: 7.450
Authors: J Curtis Nickel; Claus G Roehrborn; Michael P O'leary; David G Bostwick; Matthew C Somerville; Roger S Rittmaster Journal: J Urol Date: 2007-07-16 Impact factor: 7.450
Authors: Alessandro Tafuri; Marco Sebben; Giovanni Novella; Marco Pirozzi; Tania Processali; Aliasger Shakir; Riccardo Rizzetto; Nelia Amigoni; Riccardo Bernasconi; Matteo Brunelli; Maria A Cerruto; Salvatore Siracusano; Alessandro Antonelli; Walter Artibani; Antonio B Porcaro Journal: Arab J Urol Date: 2020-05-13
Authors: Luca Cindolo; Riccardo Bertolo; Andrea Minervini; Francesco Sessa; Gianluca Muto; Pierluigi Bove; Matteo Vittori; Giorgio Bozzini; Pietro Castellan; Filippo Mugavero; Mario Falsaperla; Luigi Schips; Antonio Celia; Maida Bada; Angelo Porreca; Antonio Pastore; Yazan Al Salhi; Marco Giampaoli; Giovanni Novella; Riccardo Rizzetto; Nicoló Trabacchin; Guglielmo Mantica; Giovannalberto Pini; Riccardo Lombardo; Andrea Tubaro; Alessandro Antonelli; Cosimo De Nunzio Journal: World J Urol Date: 2020-01-06 Impact factor: 4.226
Authors: Luigi Cormio; Luca Cindolo; Francesco Troiano; Michele Marchioni; Giuseppe Di Fino; Vito Mancini; Ugo Falagario; Oscar Selvaggio; Francesca Sanguedolce; Francesca Fortunato; Luigi Schips; Giuseppe Carrieri Journal: Front Oncol Date: 2018-10-16 Impact factor: 6.244